Review article: Current management of alcoholic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 7, 2004, Pages 707-714

  Tome, S ^a   Lucey, M R ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; COLCHICINE; CORTICOSTEROID; CYTOKINE; INFLIXIMAB; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXANDROLONE; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PREDNISOLONE; PROPYLTHIOURACIL; S ADENOSYLMETHIONINE; SERUM ALBUMIN; SILYMARIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLISM; BLOOD CLOTTING DISORDER; CAUSE OF DEATH; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEVER; FIBROGENESIS; HEPATORENAL SYNDROME; HUMAN; LEUKOCYTOSIS; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; PROTEIN SYNTHESIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ALCOHOLISM; COLCHICINE; FREE RADICAL SCAVENGERS; HEPATITIS; HUMANS; LIVER DISEASES, ALCOHOLIC; LIVER TRANSPLANTATION; PHOSPHATIDYLCHOLINES; PROGNOSIS; TEMPERANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1942470397     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01881.x     Document Type: Review

References (61)

1. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988; 8: 12-25.
2. Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann NY Acad Sci 1975; 252: 85-105.
3. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23: 1025-9.
4. Tuys A, Pequignot G. Great risk of ascitic cirrhosis in females in relation to alcohol consumption. Int J Epidemiol 1984; 13: 53-7.
5. Grove J, Daly AK, Bassendine MF, Day CP. Association of tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26: 143-6.
6. Jarvelainen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001; 33: 1148-53.
7. Bosron WF, Ehrig T, Li TK. Genetic factors in alcohol metabolism and alcoholism. Semin Liver Dis 1993; 13: 126-35.
8. Pares A, Barrera JM, Caballeria J, et al. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology 1990; 12: 1295-9.
9. Sorensen TIA. Alcohol and liver injury: dose-related or permissive effect? Br J Addiction 1989; 9: 189-97.
10. Baptista A, Bianchi L, de Groote J, et al. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981; 1: 707-11.
11. McSween RNM, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 3: 221-32.
12. Alexander JF, Lichner MW, Galambos JT. Natural history of alcoholic hepatitis. The long-term prognosis. Am J Gastroenterol 1971; 56: 515-25.
13. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomised multicenter trial. Ann Intern Med 1989; 110: 685-90.
14. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo controlled trial. Gastroenterology 2000; 119: 1637-48.
15. Mutimer DJ, Burra P, Neuberger JM, et al. Managing severe alcoholic hepatitis complicated by renal failure. Q J Med 1993; 86: 649-56.
16. Lieber CS. Biochemical factors in alcoholic liver disease. Semin Liver Dis 1993; 13: 136-53.
17. Meagher EA, Barry OP, Burke A, et al. Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest 1999; 104: 805-13.
18. Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003; 124: 778-90.
19. Nolan JP. Intestinal endotoxins as mediators of hepatic injury - an idea whose time has come again. Hepatology 1989; 10: 887-91.
20. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999; 19: 205-19.
21. Stewart SF, Leathart JB, Chen Y, et al. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology 2002; 36: 1355-60.
22. Galambos JT. Natural history of alcoholic hepatitis. III. Histological changes. Gastroenterology 1972; 63: 1026-35.
23. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987-90.
24. O'Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet 1996; 347: 237-40.
25. Fuller RK. Definition and diagnosis of relapse to drinking. Liver Transpl Surg 1997; 3: 258-62.
26. Vaillant GE. The natural history of alcoholism and its relationship to liver transplantation. Liver Transpl Surg 1997; 3: 304-10.
27. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations from the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2022-36.
28. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-9.
29. Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis. II. Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986; 43: 213-8.
30. Schenker S, Halff GA. Nutritional therapy in alcoholic liver disease. Semin Liver Dis 1993; 13: 196-209.
31. Stickel F, Hoehn B, Schuppan D, Seitz HK. Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003; 18: 357-73.
32. Cabré E, Gonzalez-Huix F, Abad-Lacruz A, et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990; 98: 715-20.
33. Cabré E, Rodriguez Iglesias P, Caballeria J, et al. on behalf of the Spanish Group for the Study of Alcoholic Hepatitis. Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enterai nutrition: a multicenter randomized trial. Hepatology 2000; 32: 36-42.
34. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113: 299-307.
35. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 26: 507-12.
36. Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe alcoholic hepatitis. J Hepatol 2002; 36: 480-7.
37. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 113-8.
38. Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984: 311: 1464-70.
39. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17: 564-76.
40. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-6.
41. Spahr L, Rubbia-Brandt L, Frossard J, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448.
42. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 419-25.
43. Stewart S, Prince M, Bassendine M, et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2002; 36(S): 16.
44. Mezey E, Potter J, Rennie Tankersley L, et al. A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology 2003; 38(S): 264A.
45. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105-13.
46. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28: 615-21.
47. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylm-ethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-9.
48. Halle P, Pare P, Kaptein E, Kanel G, Redeker AG, Reynolds TB. Double blind controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982; 82: 925-31.
49. Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987; 317: 1421-7.
50. Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease - a Cochrane Hepato-Biliary Group Review. Liver 2001; 21: 398-404.
51. Kershenobich D, Vargas F, Garcia-Tsao G, Perez Tamayo R, Gent M, Rojkind M. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988; 318: 1709-13.
52. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2001; 3: CD002148.
53. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol 2000; 32(S): 113-28.
54. Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha generation in Kupffer cells of ethanol-fed rats. Biochem Biophys Res Commun 2002; 299: 459-64.
55. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S for the Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs cooperative study of polyenylphosphatidylcholine in alcoholic liver disease. Alcoholism: Clin Exp Res 2003; 27: 1765-72.
56. Starzl TE, Van Thiel D, Tzakis AG, et al. Orthotopic liver transplantation for alcoholic cirrhosis. J Am Med Assoc 1988; 260: 2542-4.
57. Lucey MR, Carr K, Beresford TP, et al. Alcohol use after liver transplantation in alcoholics: a clinical cohort follow-up study. Hepatology 1997; 26: 192-7.
58. Neuberger J, Schulz KH, Day C, et al. Transplantation for alcoholic liver disease. J Hepatol 2002; 36: 130-7.
59. Tome S, Lucey MR. Timing of liver transplantation in alcoholic cirrhosis. J Hepatol 2003; 39: 302-7.
60. Lucey MR, Brown KA, Everson GT, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628-37.
61. Poynard T, Naveau S, Doffoel M, et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. J Hepatol 1999; 30: 1130-7.